Therapy
Female CEOs
Health

Halozyme Therapeutics

$15.61
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.31 (-1.95%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell HALO and other stocks, options, ETFs, and crypto commission-free!

About

Halozyme Therapeutics, Inc. Common Stock, also called Halozyme Therapeutics, is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. Read More It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Employees
281
Headquarters
San Diego, California
Founded
1998
Market Cap
2.27B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
802.21K
High Today
$16.01
Low Today
$15.55
Open Price
$15.73
Volume
255.51K
52 Week High
$19.56
52 Week Low
$13.24

Collections

Therapy
Female CEOs
Health
Pharmaceutical
Biopharmaceutical
Biotechnology
Medical
Technology

News

Yahoo FinanceMay 13

Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019

SAN DIEGO, May 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the Bank of America Merrill Lynch Health Care Conference 2019 in Las Vegas, NV. Laurie Stelzer, senior vice president and chief financial officer, will provide an overview of the company on Thursday, May 16 at 12:20 p.m. ET / 9:20 a.m. PT. A live webcast of the presentation can be accessed through the "Investors" section of www.halozy...

22
NasdaqMay 8

Halozyme Therapeutics (HALO) Matches Q1 Earnings Estimates

6
NasdaqMay 8

Halozyme Therapeutics Inc (HALO) Q1 2019 Earnings Call Transcript

Image source: The Motley Fool. Halozyme Therapeutics Inc (NASDAQ: HALO) Q1 2019 Earnings Call May. 7, 2019 , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon, everyone. I would now like to turn the conference over to Al Kildani, Vice President of Investor Relations and Corporate Communications for Halozyme Therapeutics. Mr. Kildani, please begin. Al Kildani -- Vice President of Investor Relations and Corporate Communications...

8

Earnings

-$0.23
$0.13
$0.49
$0.85
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
$0.01 per share
Actual
$0.01 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.